How Qinlock Targets GIST Cells
Qinlock (ripretinib) treats gastrointestinal stromal tumors (GIST) by inhibiting multiple kinases that drive tumor growth. GISTs often harbor mutations in KIT or PDGFRA genes, leading to overactive tyrosine kinases that signal uncontrolled cell proliferation. Qinlock is a broad-spectrum tyrosine kinase inhibitor that blocks these mutated kinases—primarily KIT and PDGFRA—along with secondary mutations like those at KIT exon 17 or 18 that cause resistance to earlier drugs such as imatinib, sunitinib, or regorafenib.[1][2]
It binds to the kinase domains, preventing ATP from attaching and halting downstream signals like MAPK and PI3K pathways, which starves cancer cells of growth cues and triggers cell death.[3]
Who Gets Prescribed Qinlock and When
The FDA approved Qinlock in 2020 for adults with advanced GIST who received prior treatment with three or more kinase inhibitors, including imatinib. It's a fourth-line option for tumors that have progressed despite those therapies, filling a gap where resistance mutations dominate.[1][4]
Clinical trials like INVICTUS showed it extended median progression-free survival to 6.6 months versus 1 month with placebo, with overall survival benefits emerging in follow-up data.[2]
How It Differs from Imatinib or Other TKIs
Unlike imatinib (Gleevec), which targets early KIT exon 11 mutations effectively but fails against secondary resistance mutations, Qinlock hits a wider array of KIT and PDGFRA variants simultaneously. It also inhibits VEGF receptors and MACF1, potentially curbing angiogenesis and metastasis more than single-target drugs like sunitinib.[3][5]
| Drug | Primary Targets | Best For | Common Resistance Issue |
|------|-----------------|----------|-------------------------|
| Imatinib | KIT exon 11 | First-line | Secondary mutations (exons 13/17) |
| Sunitinib | KIT, VEGFR | Second-line | Broad resistance |
| Regorafenib | KIT, VEGFR, PDGFRA | Third-line | Exon 17 mutations |
| Qinlock | Pan-KIT/PDGFRA + switches | Fourth-line | Overcomes prior resistances [5] |
Common Side Effects Patients Report
Patients experience hand-foot skin reactions (47%), diarrhea (41%), nausea (41%), abdominal pain (34%), and hypertension (28%), mostly grade 1-2 and manageable with dose adjustments. Hair depigmentation affects over 40%, but it's reversible. Severe events like intracranial hemorrhage are rare (<1%).[1][2]
When Does Qinlock's Patent Expire
Qinlock's key composition-of-matter patent (US 8,461,157) expires in 2027, with formulation patents extending protection possibly to 2033-2035. DrugPatentWatch tracks ongoing challenges; no generics approved yet, but ANDA filings could trigger litigation.[6]
[1]: FDA Label for Qinlock (ripretinib), 2020. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213973s000lbl.pdf
[2]: INVICTUS trial, Lancet Oncol, 2020. https://pubmed.ncbi.nlm.nih.gov/32888466/
[3]: Qinlock mechanism review, Nat Rev Clin Oncol, 2021. https://pubmed.ncbi.nlm.nih.gov/34079125/
[4]: NCCN Guidelines for GIST, Version 2.2023. https://www.nccn.org/guidelines
[5]: Comparative TKI review, J Clin Oncol, 2022. https://ascopubs.org/doi/10.1200/JCO.21.02758
[6]: DrugPatentWatch.com - Ripretinib patents. https://www.drugpatentwatch.com/p/tradename/QINLOCK